Castle Biosciences CSTL Business Segments — Income tax expense (benefit)

Similar metrics at other companies

NEOReportable Segment — Income tax expense (benefit)

-$472K-277%

ADTReportable Segment — Income tax expense (benefit)

$58.11M+13.9%

GPORReportable Segments — Income Tax Expense (Benefit)

$44.68M+25,488%

ELANReportable Segment — Income tax expense (benefit)

$30M+529%

LOGIReportable Segment — Income Tax Expense (Benefit)

$6.39M—

SREReportable Segment — Income tax expense (benefit)

$69M+81.6%

Questions, answered.

What is Castle Biosciences's business segments — income tax expense (benefit)?

Castle Biosciences (CSTL) reported business segments — income tax expense (benefit) of $109K in Q1 2026.

How has Castle Biosciences's business segments — income tax expense (benefit) changed year-over-year?

Castle Biosciences's business segments — income tax expense (benefit) increased by 125.8% year-over-year, from -$423K to $109K.

What is the long-term trend for Castle Biosciences's business segments — income tax expense (benefit)?

Over 2 years (2022 to 2025), Castle Biosciences's business segments — income tax expense (benefit) has grown at a 74.2% compound annual growth rate (CAGR), from -$1.77M to -$5.36M.

What does business segments — income tax expense (benefit) mean?

This reflects the provision for income taxes or the benefit recognized specifically attributable to the reportable segment's operations. It indicates the tax impact of the segment's profitability and regulatory environment on the overall corporate financial results.